Entity

Time filter

Source Type

Pittsburgh, PA, United States

Patent
Thar Pharmaceuticals | Date: 2013-10-07

Novel crystalline forms of tadalafil suitable for pharmaceutical compositions in drug delivery systems for humans.


Patent
Thar Pharmaceuticals | Date: 2010-07-30

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.


Patent
Thar Pharmaceuticals | Date: 2013-03-14

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.


Shan N.,Thar Pharmaceuticals | Perry M.L.,Thar Pharmaceuticals | Perry M.L.,University of Limerick | Weyna D.R.,Thar Pharmaceuticals | Zaworotko M.J.,University of Limerick
Expert Opinion on Drug Metabolism and Toxicology | Year: 2014

Introduction: Pharmaceutical cocrystallization has emerged in the past decade as a new strategy to enhance the clinical performance of orally administered drugs. A pharmaceutical cocrystal is a multi-component crystalline material in which the active pharmaceutical ingredient is in a stoichiometric ratio with a second compound that is generally a solid under ambient conditions. The resulting cocrystal exhibits different solid-state thermodynamics, leading to changes in physicochemical properties that offer the potential to significantly modify drug pharmacokinetics. Areas covered: The impact of cocrystallization upon drug pharmacokinetics has not yet been well delineated. Herein, we compile previously published data to address two salient questions: what effect does cocrystallization impart upon physicochemical properties of a drug substance and to what degree can those effects impact its pharmacokinetics. Expert opinion: Cocrystals can impact various aspects of drug pharmacokinetics, including, but not limited to, drug absorption. The diversity of solid forms offered through cocrystallization can facilitate drastic changes in solubility and pharmacokinetics. Therefore, it is unsurprising that cocrystal screening is now a routine step in early-stage drug development. With the increasing recognition of pharmaceutical cocrystals from clinical, regulatory and legal perspectives, the systematic commercialization of cocrystal containing drug products is just a matter of time. © 2014 Informa UK, Ltd. Source


Patent
Thar Pharmaceuticals | Date: 2013-02-13

Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Discover hidden collaborations